Skip to main content
Caplight Logo









Endo Axiom

Endo Axiom

Private
SydneyHealthcare & Life Scienceshttps://www.endoaxiom.com/

Last Round

Grant

Jun 30, 2025

Total Funding Raised

$2.22M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Endo Axiom is a biotechnology company developing platforms for the oral delivery of drugs and biologics, including an oral smart insulin and an immune modulation platform to prevent type one diabetes.

Sector

Healthcare & Life Sciences

Verticals

EHR & EMR, Medical Imaging, Vertical SaaS

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug deliveryoral insulinnanotechnologybiologicstherapeutic platformpreclinical researchclinical trialspharma pipelinebiotech startupdrug developmentoral drug delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endo Axiom Comparables

Compare Endo Axiom with similar companies based on industry and business-model similarity.

Endo Axiom comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fortive Corporation
79%
NewCura
78%
Utech Products, Inc.
76%

Endo Axiom Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 30, 2025
SeedApr 18, 2023

Key People

Founding team and executive leadership

Nicholas Hunt

Chief Executive Officer

Executive Team

Endo Axiom Investors

Notable investors and investment history

Endo Axiom investors
InvestorRounds
Proto AxiomSeed
MTPConnectGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors grew 106% MoM, reaching 2.4K.

  • May 16, 2026

    Monthly visitors increased 151% MoM, reaching 1.2K.

Recent news

Latest coverage and updates

  • partners_withSep 11, 2026

    Endo Axiom Pty Ltd. partnered with Abinitio on Jul 1st '24.

Endo Axiom Filings

Explore SEC and related filing metadata, where available.

Endo Axiom filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Endo Axiom's valuation, stock price, and market status.

Is Endo Axiom a public or private company?

Endo Axiom is a private company.

What is the current stock price of Endo Axiom?

Endo Axiom is a private company with no public stock price. No recent secondary market data is available.

How much is Endo Axiom worth (valuation)?

Valuation information for Endo Axiom is not publicly available.

Can I buy Endo Axiom stock?

Endo Axiom shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Endo Axiom's last funding round?

Endo Axiom's most recent funding round was Accelerator on April 18, 2023.

Who are the main investors in Endo Axiom?

Key investors in Endo Axiom include Proto Axiom.

Will Endo Axiom IPO soon?

No public IPO plans have been announced for Endo Axiom.

How can I track Endo Axiom secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Endo Axiom's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSydney
Employee Range2
Year Founded2023
Last FundingJun 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?